AtCor Medical Holdings Limited Debuts WISDOM System

ITASCA, IL and SYDNEY, AUSTRALIA--(Marketwire - May 19, 2009) - AtCor Medical Inc. (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, today announced the introduction of the WISDOM* system, a secure data transfer and storage network that links the company, clinical trial sites and its pharmaceutical and medical device clients.

The WISDOM system allows SphygmoCor test results to be transferred instantaneously at the click of button for quality review, processing and transmittal to trial sponsors. AtCor Medical's clinical trial training and data management team now has the capability of remote assessment and operator coaching during quality assurance evaluations and patient visits.

With WISDOM, trial data security is enhanced. Test results can be transmitted from the study site and stored centrally after each test. Trial data is protected, even if a catastrophic event should occur at an investigator site.

"AtCor Medical's SphygmoCor® system is the global gold standard for noninvasive central blood pressure and pulse wave velocity assessment in clinical trials and in patient care," said Duncan Ross, AtCor Medical CEO. "The WISDOM system is a reflection of our commitment to provide the gold standard in service, as well as in technology, in support of clinical trials. WISDOM offers enhanced data quality, security and speed."

WISDOM -- today clinical trials, tomorrow clinical practice

"Looking to the future, the WISDOM system will give us a new capability in our offering to the clinical market," Ross continued. "With remote transmission, physician practices will be able to transmit data for review by experts in central blood pressure assessment. The system also offers the capability of remote collection and sorting of testing and outcomes data, which could be an invaluable patient management tool."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinical to measure central blood pressure noninvasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects that cannot be detected with standard blood pressure monitoring.

More than 1,900 SphygmoCor systems are currently in use worldwide at major medical and research institutions and in clinical trials with leading pharmaceutical companies. The companies technology has been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in the United States, Australia, and Europe. For further information, please visit our web site at www.atcormedical.com.

*Acronym: Worldwide Instantaneous Study Data Operations Management